News

Search For News


TRY IT NOW

Sign up online today & collaborate

or click here to find out more

Search results for {{term}}

1. Inivata Completes £31.5 Million ($45M) Series A Fundraising Round

Inivata Completes £31.5 Million ($45M) Series A Fundraising Round26/01/2016Funds to Drive Clinical Development of New Approaches to Improve Cancer Treatment and Outcomes through Liquid BiopsiesInivata Limited, a clinical cancer genomics company employing the precision of circulating tumour DNA (“ctDNA”) analysis to improve personalized healthcare in oncology, today announced the completion of a Series A fundraising of £31.5 Million ($45M). Existing investors Imperial Innova


2. Adaptimmune and GSK Expand Strategic Immunotherapy Collaboration

Adaptimmune and GSK Expand Strategic Immunotherapy Collaboration02/02/2016London, UK, Philadelphia, USA. and Oxford, UK,  – Adaptimmune Therapeutics plc, a leader in the use of T- cell receptor (TCR) engineered T-cell therapy to treat cancer, and GlaxoSmithKline plc today announced that the companies have expanded the terms of their strategic collaboration agreement to accelerate Adaptimmune’s lead clinical cancer program, an affinity enhanced T-cell immunotherapy (GSK3377794) t


3. OxLEP Announces New Chair

OxLEP Announces New Chair 04/03/2016 Oxford, UK – Oxfordshire Local Enterprise Partnership (OxLEP) announces the appointment of Jeremy Long as the new OxLEP Chair.Jeremy Long is Chief Executive of European Business for MTR Corporation, he is succeeding Adrian Shooter who stepped down in October 2014 following the completion of his five year term.OxLEP is the strategic business-led organisation focusing on county wide economic growth; Mr Long outlined his desire to use his experie


4. Summit Announces Further US Patent Granted for CDI Antibiotic Ridinila

Summit Announces Further US Patent Granted for CDI Antibiotic Ridinilazole 28/04/2016Oxford, UK – Summit Therapeutics plc (AIM: SUMM, NASDAQ: SMMT), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy (‘DMD’) and Ridinilazole is a novel class antibiotic with potential for broad use in the treatment of CDI. In a Phase 2 clinical trial, ridinilazole showed statistical superiority over vancomycin in rates of sustained


5. Bevespi Aerosphere Approved by the US FDA for Patients with COPD

Bevespi Aerosphere Approved by the US FDA for Patients with COPD 25/04/2016AstraZeneca today announced that the US Food and Drug Administration has approved Bevespi Aerosphere (glycopyrrolate and formoterol fumarate) inhalation aerosol indicated for the long-term, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema.Sean Bohen, Executive Vice-President, Global Medicines Development and Chief



Page 10 of 30 ( 148 results in total )
© Catalyst Innovation Portal 2018